JAZZ Jazz Pharmaceuticals plc

146.41
+0.41  (+0%)
Previous Close 146
Open 146.42
Price To Book 2.71
Market Cap 8,282,812,082
Shares 56,572,721
Volume 9,065
Short Ratio
Av. Daily Volume 529,749
Stock charts supplied by TradingView

NewsSee all news

  1. Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

    DUBLIN, Jan. 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking marketing

  2. PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

    MADRID and DUBLIN, Jan. 22, 2020 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended

  3. Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

    DUBLIN, Jan. 20, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the European Commission approved Sunosi® (solriamfetol) to improve wakefulness and reduce excessive daytime sleepiness

  4. Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    DUBLIN, Jan. 6, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will be webcasting its corporate presentation at the 38th Annual J.P. Morgan Healthcare Conference in San

  5. Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    DUBLIN, Dec. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study for JZP-458, a recombinant Erwinia

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA filing submitted January 21, 2020.
JZP-258
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
CRL received October 11, 2010.
JZP-6
Fibromyalgia
Phase 2 enrollment initiation announced February 8, 2017.
JZP-110
Excessive Sleepiness in Parkinson's Disease
FDA Approval announced October 26, 2018.
Xyrem
Pediatric narcolepsy patients with cataplexy
Phase 3 data released March 20, 2017 - primary endpoints met.
JZP-110
Excessive sleepiness associated with obstructive sleep apnea
FDA Approval announced March 20, 2019.
JZP-110
Excessive sleepiness associated with narcolepsy
Phase 3 interim analysis due 1H 2020.
Defibrotide
VOD in high-risk patients following hematopoietic stem cell transplantation
Approval announced August 3, 2017.
Vyxeos
Acute myeloid leukemia
Phase 2 enrolment completed 3Q 2019.
Defibrotide
acute Graft-versus-Host-Disease (aGvHD)
Phase 3 commencement of enrolment announced November 29, 2018.
JZP-258
Idiopathic Hypersomnia
Phase 1/2 presentation at ASCO May 31, 2019.
CPX-351
Acute myeloid leukemia (AML)
Phase 1b ongoing.
Vyxeos in combination with venetoclax
First-line unfit Acute myeloid leukemia
Phase 2/3 commencement of enrolment announced December 30, 2019.
JZP-458
Acute lymphoblastic leukemia (ALL)
Phase 2 commencement of enrolment announced October 10, 2019.
Defibrotide
CAR-T associated neurotoxicity in diffuse large B-cell lymphoma (DLBCL) patients
Phase 2b trial to be initiated in 2020.
JZP-385
Essential Tremor
NDA filed by partner PharmaMar - December 2019.
Lurbinectedin
Small cell lung cancer (NSCLC)

Latest News

  1. Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

    DUBLIN, Jan. 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking marketing

  2. PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

    MADRID and DUBLIN, Jan. 22, 2020 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended

  3. Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

    DUBLIN, Jan. 20, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the European Commission approved Sunosi® (solriamfetol) to improve wakefulness and reduce excessive daytime sleepiness

  4. Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    DUBLIN, Jan. 6, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will be webcasting its corporate presentation at the 38th Annual J.P. Morgan Healthcare Conference in San

  5. Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    DUBLIN, Dec. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study for JZP-458, a recombinant Erwinia

  6. PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.

    MADRID and DUBLIN, Dec. 19, 2019 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that PharmaMar and Jazz Pharmaceuticals Ireland Limited have entered into an exclusive

  7. Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

    DUBLIN, Nov. 15, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion

  8. Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences

    DUBLIN, Nov. 14, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will webcast its corporate presentations at three upcoming investor conferences. Jefferies 2019 London

  9. Jazz Pharmaceuticals to Highlight Growing Hematology Oncology Pipeline at ASH 2019 Annual Meeting

    DUBLIN, Nov. 7, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that 15 abstracts sponsored by Jazz Pharmaceuticals, including one oral presentation, one abstract from a collaboration trial

  10. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity

    DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the first patient has been enrolled in an exploratory Phase 2 clinical trial evaluating the ability of defibrotide to

  11. Jazz Pharmaceuticals Survey Highlights Prevalence of Misinformation and Misperception About Narcolepsy Among Americans

    DUBLIN, Sept. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the results of a consumer survey of more than 1,000 Americans measuring public perception and knowledge of sleep disorders

  12. Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019

    DUBLIN, Sept. 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that positive data from the Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and

  13. Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

    DUBLIN, Aug. 27, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. Wells Fargo Securities